A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Adult
Aged
Albumins
/ administration & dosage
Antineoplastic Agents, Phytogenic
/ administration & dosage
Area Under Curve
Cohort Studies
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Infusions, Parenteral
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Neutropenia
/ chemically induced
Paclitaxel
/ administration & dosage
Peritoneal Neoplasms
/ drug therapy
Severity of Illness Index
Treatment Outcome
Intraperitoneal chemotherapy
Nab-paclitaxel
Peritoneal carcinomatosis; ovarian cancer
Pharmacologic advantage
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
30
08
2018
accepted:
02
01
2019
pubmed:
10
1
2019
medline:
1
1
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that are primarily confined to the peritoneal cavity in a phase I trial. Using a 3 + 3 dose escalation of IP nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle, we evaluated six dose levels (35-175 mg/m There were no dose-limiting toxicities (DLTs) in cohorts 1-3. There was a DLT in one of six patients in cohort 4 (112.5 mg/m Weekly IP nab-paclitaxel has a favorable toxicity profile, a significant pharmacologic advantage, and promising clinical activity. NCT00825201.
Identifiants
pubmed: 30623229
doi: 10.1007/s00280-019-03767-9
pii: 10.1007/s00280-019-03767-9
pmc: PMC8919712
mid: NIHMS1770746
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Antineoplastic Agents, Phytogenic
0
Paclitaxel
P88XT4IS4D
Banques de données
ClinicalTrials.gov
['NCT00825201']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-598Subventions
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Références
Cancer Treat Res. 1996;81:1-5
pubmed: 8834570
Gan To Kagaku Ryoho. 2014 Nov;41(12):2251-3
pubmed: 25731486
J Clin Oncol. 2001 Feb 15;19(4):1001-7
pubmed: 11181662
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
J Clin Oncol. 1992 Sep;10(9):1485-91
pubmed: 1355523
J Clin Oncol. 1995 Dec;13(12):2961-7
pubmed: 8523061
Eur J Surg Oncol. 2003 Apr;29(3):261-5
pubmed: 12657237
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
J Clin Oncol. 2015 Sep 10;33(26):2841-7
pubmed: 26240233
Clin Breast Cancer. 2007 Dec;7(11):850-6
pubmed: 18269774
Br J Surg. 2017 May;104(6):669-678
pubmed: 28407227
Clin Cancer Res. 2006 Feb 15;12(4):1317-24
pubmed: 16489089
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901
pubmed: 14676112
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):213-8
pubmed: 18191625
Cancer Res. 1998 Jul 1;58(13):2793-800
pubmed: 9661893
Gynecol Oncol. 2002 Jun;85(3):517-23
pubmed: 12051884
N Engl J Med. 1996 Dec 26;335(26):1950-5
pubmed: 8960474
Recent Results Cancer Res. 2007;169:53-73
pubmed: 17506249
Clin Cancer Res. 2007 Feb 15;13(4):1232-7
pubmed: 17317834
Oncol Rep. 2014 Jul;32(1):89-96
pubmed: 24859429
J Clin Oncol. 1987 May;5(5):756-67
pubmed: 3572465
Lancet Oncol. 2013 Sep;14(10):1020-6
pubmed: 23948349
Gan To Kagaku Ryoho. 2002 Nov;29(12):2164-7
pubmed: 12484028
Gynecol Oncol. 2011 Jul;122(1):111-5
pubmed: 21497382
J Clin Oncol. 2009 Mar 20;27(9):1426-31
pubmed: 19224848
Arch Gynecol Obstet. 2018 Aug;298(2):243-257
pubmed: 29869089
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300